Towards Personalised Medicine: iCarbonX chooses Malta as the first international base
iCarbonX has chosen Malta as the first international base of a project aimed at developing an artificial intelligence platform to facilitate research related to the treatment of diseases, preventive care and precision nutrition. This approach is considered as an essential element to enable the future development of personalized medicine.iCarbonX founder and CEO Dr Jun Wang was the co-founder and former CEO of genome-sequencing powerhouse BGI that in 2013 acquired California-based Complete Genomics.
